CEI Weekly: Is There a Future for Generic Biotech Crops?
FEATURE: Is There a Future for Generic Biotech Crops?
Usually when patents expire, new generic markets are allowed to develop. But in the case of crop biotechnology, current U.S. regulatory policy could prevent a market of affordable generic biotech seeds. CEI Senior Fellow Greg Conko explains the situation and proposes regulatory reforms in a new CEI Issue Analysis: "Is There a a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry."
David Bier's op-ed in The Washington Examiner
Bill Frezza's op-ed in Forbes
Trey Kovacs' op-ed in The Daily Caller
Matt Patterson's op-ed in The Washington Examiner
Matt Patterson & Crissy Brown's op-ed in The Washington Times
Fred Campbell's op-ed in Ars Technica
John Berlau's citation in The Washington Free Beacon
Ryan Radia's citation in CNET
Hans Bader's citation on HotAir
Senior Fellow Greg Conko discusses his newpaper, “Is There a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry.” Patents will soon expire for several popular biotech crops, opening the way for cheaper generic versions. But because, unlike prescription drugs, biotech crops have to be re-approved every few years, the future of generic biotech crops is very much in doubt. Conko recommends getting rid of re-approval requirements to put them on the same footing as other products.
BEST OF THE BLOGS
By Angela Logomasini
By Hans Bader
By Marc Scribner
By Hans Bader